Melanotan-2 Cost in the US

The short answer on cost

For almost every other compound on this site, a “cost” page is a comparison: what a telehealth program charges per month, what an in-person clinic adds once you count consults and labs, and what a 503A compounding pharmacy bills to fill the prescription. Melanotan-2 breaks that template completely, because none of those routes exist for it.

Melanotan-2 is not FDA-approved for any use, and it is not eligible to be compounded by a licensed pharmacy. That means there is no prescriber to pay, no pharmacy invoice, and no clinic program — and so there is no legitimate US “price” at all. The only number you will find is a gray-market vendor’s vial price, sold under a “research use only, not for human consumption” label. As of 2026 those listings run roughly $15-60 for a 10 mg vial, plus shipping. That figure is real, but it is misleading: it is the price of an unregulated chemical, not the price of a treatment.

Note: A low sticker price is the single most consistent feature of Melanotan-2 marketing, and it is the easiest part to misread. The reason it is cheap is that everything that would make it a medicine has been removed.

Why there is no pharmacy or telehealth price

To have a real US cost, a peptide has to be prescribable or compoundable. Melanotan-2 is neither.

It was removed from the FDA’s Category 2 “do not compound” list in 2026, but removal from that list did not make it compoundable. It was not placed in the enforcement-discretion bucket that covers Category 1 substances, it is not on the 503A bulk-drug-substances list pharmacies may compound from, and it was not part of the July 23-24, 2026 PCAC review batch. A separate PCAC review is expected later, but even a favorable vote there would only begin federal rulemaking, not authorize compounding. Until that process completes, no compounding pharmacy can legally fill a Melanotan-2 order, so no pharmacy can quote you a price.

Because there is no fillable prescription, there is also no telehealth price. A legitimate telehealth peptide program works by connecting you to a licensed prescriber whose order a pharmacy fills. With nothing to prescribe and nothing to fill, that model simply cannot run for Melanotan-2. Any website advertising a Melanotan-2 “telehealth program,” “membership,” or “monthly plan” is not selling a clinical service — it is selling the same gray-market vial with a healthcare-shaped wrapper around it. The presence of a checkout cart and a “consult” does not create a legal route; it just adds margin. (For the full breakdown of why every access channel is closed, see how to get Melanotan-2 in the US, and for the prescription mechanics specifically, does Melanotan-2 need a prescription?.)

What the gray-market price actually buys

The $15-60 vial is cheap precisely because it omits every cost that turns a peptide into a medicine. It is worth being explicit about what those omitted costs are, because they are the difference between a research chemical and a treatment.

A regulated peptide’s price reflects pharmaceutical-grade (GMP) manufacturing, batch-by-batch purity and potency testing, sterile fill-and-finish, a prescriber’s evaluation, and a licensed pharmacy’s accountability. A gray-market Melanotan-2 vial reflects none of those reliably. Independent analysis has repeatedly found that what is in the vial does not match the label: in one well-known study, vials labeled 10 mg contained measured peptide content ranging from roughly 4 to 9 mg, and similar inaccuracy has shown up across samples. Some vendors publish a certificate of analysis (COA), but a COA from an unaccountable seller is a marketing document, not a regulatory guarantee — there is no authority verifying it and no recourse if it is wrong.

So when you pay the low price, you are not buying a known quantity of a known compound. You are buying an unknown quantity of something that may or may not be the cyclic peptide it claims to be, at a purity you cannot independently confirm. The cheapness is the unverifiability. That is not a bargain version of a medicine; it is a different category of product.

The hidden costs the sticker price ignores

Two costs never appear on the vendor’s checkout page, and both can dwarf the vial price.

The first is medical risk. Melanotan-2 carries its own documented harm record, separate from any supply concern: published case reports and regulator warnings link it to acute kidney injury, rhabdomyolysis, ischemic priapism, and — most relevant to a tanning product — darkening of existing moles and the appearance of new ones, which is a melanoma-monitoring concern. None of that risk is priced into a $30 vial, but it is very real, and managing it (dermatology visits, mole mapping, treating an adverse event) is a cost a regulated pathway would have helped you avoid. The clinical side of this is covered in detail on Melanotan-2 side effects.

The second hidden cost is the absence of oversight itself. With a prescribed, dispensed medicine, you are paying partly for a clinician who screens you, monitors you, and is accountable if something goes wrong. The gray-market price strips that out entirely — “no evaluation, just buy and inject” is the whole pitch, and it is also the whole problem. There is no one checking whether the product is right for you, whether your moles are changing, or whether a dose of an unknown concentration is doing something it shouldn’t.

What regulated alternatives cost — for context

It helps to compare against melanocortin drugs that do have a legitimate price, because it shows what the Melanotan-2 number is really standing in for.

Bremelanotide (brand name Vyleesi) is an FDA-approved melanocortin-receptor drug for a specific sexual-health indication. It is a real prescription medicine, evaluated in clinical trials, dispensed through pharmacies, and — depending on insurance and program eligibility — billable in the normal way. Afamelanotide (brand name Scenesse) is FDA-approved for a rare light-sensitivity condition and is administered as a prescription implant through specialist providers. Both cost more than a gray-market vial, and that gap is the point: the extra cost is approval, testing, oversight, and accountability. If your underlying goal is sexual function rather than tanning, the approved, trial-backed route is worth understanding first — see how to get PT-141 (bremelanotide) and what is PT-141?.

There is no FDA-approved injectable specifically for cosmetic tanning. The honest comparison for the tanning goal is not “cheap MT-2 versus expensive medicine” — it is “an unregulated injectable with a real harm record versus a topical sunless tanner (DHA) that carries none of that risk.” On that comparison, the vial price stops looking like a saving.

How to read a Melanotan-2 “price” online

A few patterns are worth recognizing when you see Melanotan-2 priced on a website.

A price quoted per milligram (commonly a few dollars per mg) or per 10 mg vial, under a “research use only” disclaimer, is a gray-market listing regardless of how clinical the surrounding site looks. A “monthly cost,” “program price,” or “membership” framing is a retail wrapper, not evidence of a prescription pathway — the pathway does not exist. And a price presented as a saving versus telehealth is leaning on a comparison that is false at its root, because there is no telehealth price to be cheaper than.

The useful way to think about Melanotan-2 cost in 2026 is therefore not “how do I find the lowest vial price.” It is: the sticker is low because the product is unregulated and unverified, the real costs (risk, no oversight) are off the receipt, and the genuinely priced options in this space are the approved drugs that go through real channels. For the broader legal picture behind all of this, see are peptides legal in the US? and the 2026 FDA peptide reclassification.